A frequent deletion of complement factor H (CFH) related genes CFHR3 and CFHR1
Introduction
Age related macular degeneration (AMD, OMIM #603075) is a prevalent cause of visual impairment in older individuals of industrialized countries (1) . Several studies have identified the complement factor H (CFH) gene on chromosome 1q31 as a major AMD susceptibility gene (2) (3) (4) (5) . At this locus, the common single nucleotide polymorphism (SNP) rs1061170:T>C (Y402H) was identified as the putative risk variant. A plethora of studies have replicated these initial findings and initial reports on functional consequences of the Y402H amino acid change demonstrated reduced heparin and CRP binding of the risk variant (6) (7) (8) (9) . However, the potential risk modifying role of the common protective haplotypes at the CFH locus is still unknown.
A common copy number polymorphism (CNP) downstream of CFH encompasses an 84 kb region that includes the CFH-related genes CFHR3 and CFHR1. This CNP (ΔCFHR3/CFHR1) is of particular interest as the corresponding deletion is reported to exclusively occur on one of two common protective CFH haplotypes. This possibly highlights an independent mechanism of action unrelated to the CFH:His402 risk variant (10) (11) (12) . It is unclear, however, whether the deletion carrying haplotype alters AMD risk independently of rs1061170 (10) , or whether the deletion itself has a protective effect at least partially caused by the strong causative effect of the rs1061170:C allele (11) . Interestingly, the ΔCFHR3/CFHR1 also represents a risk factor for an autoimmune form of the severe kidney disease atypical hemolytic uremic syndrome, called DEAP-HUS (13, 14) . Most HUS patients with this chromosomal deletion have autoantibodies to factor H. These autoantibodies bind to by guest on September 23, 2016 http://hmg.oxfordjournals.org/ Downloaded from the copy number variation (CNV) and polymorphisms on AMD risk, we also included rs1061170 and rs2274700:G>A (CFH:A473A), two of the most pronounced factor H risk determinants in a logistic regression calculation (3, 4, 10, 24, 25) . As ΔCFHR3/CFHR1 represents an excellent candidate for a functional variant, we further aimed to define the function of the CFHR3 protein, identify its role in complement activation and compare the function of CFHR3 with that of CFHR1 and factor H.
We now confirm that ΔCFHR3/CFHR1 confers a reduced risk for AMD. Furthermore, we show that this protective effect is independent of both risk variants rs1061170 and 
Results

ΔCFHR3/CFHR1 is in strong LD with CFH SNPs rs1061170, rs2274700 and rs412852
To assess linkage disequilibrium (LD) between CFH SNPs and ΔCFHR3/CFHR1, we resorted to CFH genotypes determined previously in 110 AMD patients and 67 controls (26) and additionally established the CNP status for ΔCFHR3/CFHR1 by multiplex ligation-dependent probe amplification (Table S1 ). In this cohort, we observed LD between the three CFH SNPs rs1061170, rs2274700, rs412852 and ΔCFHR3/CFHR1 but not between ΔCFHR3/CFHR1 and SNPs rs800292, rs1048663, and rs11582939 ( Figure 1 ) (26) .
Haplotype analysis revealed ΔCFHR3/CFHR1 to occur predominantly on one of the two protective haplotypes (P2) (Table S2 ) confirming previous studies (11, 12) . To further dissect the dependencies between ΔCFHR3/CFHR1 and the major risk variant rs1061170 as well as the major protective variant rs2274700 (3, 10, 24, 25) , we increased the sample size by genotyping an additional 420 AMD patients and 246 matched controls for ΔCFHR3/CFHR1 and the two SNPs rs1061170 and rs2274700. This indicates that the protective effect of rs2274700 has a greater influence on AMD risk than rs1061170. Considering that the two haplotypes P1 and P2 are uniquely tagged by the rs2274700:A allele (Table S2) , this suggests that the protective effect of rs2274700 represents a combined effect of the two common protective haplotypes.
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In summary, our results show that ΔCFHR3/CFHR1 is associated with a decreased risk for AMD, and is independent of the strong risk variant rs1061170. This indicates that the absence of CFHR1 and/or CFHR3 confers beneficial effects for an AMD risk.
To clarify the role of CFHR3 and CFHR1 in complement regulation, we determined the function of the CFHR3 plasma protein and compared CFHR3 function with that of CFHR1 and factor H.
CFHR3 is a complement regulator
To define whether CFHR3 displays complement regulatory activities hemolysis assays were performed with sheep erythrocytes and factor H depleted plasma (7).
The effect of CFHR3 on complement mediated hemolysis was analyzed by adding CFHR3 to factor H depleted, complement active plasma and sheep erythrocytes. Figure 1C) . These data show that CFHR3 is a complement inhibitor.
CFHR3 neither dissociates nor 'freezes' activity of the C3 convertase
To define the regulatory function of CFHR3, the effect of CFHR3 on C3 convertase activity was investigated. A C3 convertase was formed by incubating purified proteins C3b, factor B, factor D and properdin. Then the effect of CFHR3 used at increasing concentrations (10 -50 µg/ml) on the C3 convertase stability was assayed by monitoring bound factor B. CFHR3 did not dissociate the C3 convertases as demonstrated by constant amounts of factor Bb bound to the preformed C3 convertase ( Figure 2B ). Thus, CFHR3 lacks decay activity. Similarly, neither CFHR1
nor BSA did dissociate the preformed C3 convertases ( Figure 2B ). As expected, factor H displayed decay acceleration activity and dissociated the C3bBb complex ( Figure 2B ).
To determine whether CFHR3 'freezes' C3 convertase activity in a different way than by decay acceleration, the effect of CFHR3 on a preformed C3 convertase was measured by following C3a generation. In the presence of CFHR3 C3a levels remained constant and cleavage of C3 was unaffected ( Figure 2C ). Also CFHR1 did not dissociate or 'freeze' the C3 convertase ( Figure 2C ). In contrast in the presence of factor H, which exerts decay accelerating activity, C3a generation was reduced ( Figure 2C ). The specificity of the effect was demonstrated by C3a generation in the absence of regulatory proteins and by the lack of cross-reactivity of the factor Bb antibody to C3b ( Figure 2C ). Thus, CFHR3 does not 'freeze' C3 convertase activity upon cleavage of the substrate C3.
CFHR3 displays cofactor activity for the serine protease factor I (CFI)
As CFHR3 did not restrict C3 convertase activity, the role of CFHR3 as a cofactor for factor I in cleavage of C3b was investigated. CFHR3 was incubated with C3b and factor I, the reaction mixtures were separated by SDS PAGE, transferred to a membrane and cleavage products of C3b were assayed. CFHR3 showed cofactor activity for factor I mediated cleavage of C3b and cleavage products of 68 and 43 kDa as well as 41 kDa were generated. This effect was dose dependent ( Figure 2D ).
CFHR1 used at the same concentrations lacked cofactor activity and no C3b cleavage was detected ( Figure 2D , displayed cofactor activity and cleavage products of 68, 43 and 41 kDa were generated ( Figure 2D ). Thus, CFHR3 acts as cofactor for factor I in the degradation of C3b.
CFHR3 and CFHR1 inhibit C5a generation
We next asked whether CFHR3 as a regulator of the C3 convertase affects C5a generation. C5b initiates the generation of the terminal complement complex TCC, and C5a is a potent anaphylatoxin that attracts neutrophils to the side of infection and initiates and enhances inflammatory reactions. Thus the role of CFHR3 on C5 convertase activity was followed by assaying C5a levels. CFHR3 was added to sheep erythrocytes that were incubated in complement active, factor H depleted human plasma and C5a generation was monitored by ELISA. CFHR3 at a molar concentration of 1.6 µM reduced C5a generation by approximately 63 % ( Figure 3A ).
Similarly, CFHR1 (1.8 µM) and factor H (0.5 µM) reduced C5a levels by about 60 % ( Figure 3A ).
CFHR3 and CFHR1 act anti inflammatory
To explore whether the reduced C5a generation in response to CFHR3 mediated complement inhibition has a functional impact, the inflammatory effect of factor H depleted plasma after addition of CFHR3 was assayed for neutrophil chemotaxis (see Figure 3A , column 2). CFHR3 treated plasma (1:4 dilution) inhibited neutrophil migration by 56% ( Figure 3B ) as compared to BSA treated plasma ( Figure 3B ).
Similarly, CFHR1 and factor H treated plasma reduced neutrophil migration by 64%
and by 81% ( Figure 3B ). These data demonstrate that CFHR3 and CFHR1 reduce the generation of C5a and consequently block complement mediated chemotaxis of neutrophils.
CFHR3 and CFHR1 compete with factor H for binding to C3b
As CFHR3 like CFHR1 and factor H binds to C3b, we measured whether CFHR3 and CFHR1 affect factor H binding to C3b. Binding of constant amounts of factor H was assayed in the presence of increasing concentrations of CFHR3 or CFHR1. C3b bound proteins were quantified by ELISA using specific antibodies. CFHR3
competed with factor H, as indicated by decreased binding of factor H and increased binding of CFHR3 to C3b ( Figure 4A ). Similarly, CFHR1 dose-dependently reduced factor H binding to C3b ( Figure 4B ). Thus, CFHR3, CFHR1 and factor H, which bind to the same ligand C3b, compete for binding. This result also suggests a competitive binding to C3b in plasma.
CFHR3 and CFHR1 reduce factor H mediated complement control
Based on the competitive binding of CFHR3, CFHR1 and factor H to C3b, we hypothesized that the absence of CFHR3 and CFHR1 in plasma influences factor H binding to C3b and thereby enhance complement regulation. Thus, decay acceleration activity of factor H was determined upon increasing the concentration of CFHR3 or CFHR1, which can replace factor H in C3b binding but which do not dissociate the C3 convertase. Decay acceleration activities were measured by bound factor Bb to the preformed C3 convertases. Fragment Bb binding was significantly increased when CFHR3 or CFHR1 was incubated with the preformed convertases in the presence of constant amounts of factor H ( Figure 4C ). Thus CFHR3 and CFHR1 modulate the C3 convertase activity in human plasma. The C3a level increased with elevated amounts of CFHR3 or CFHR1 in ΔCFHR3/CFHR1 plasma, but the level was reduced when factor H was added ( Figure 4D ).
Discussion
Here, we show that the common CNP ΔCFHR3/CFHR1 on chromosome 1q32 is protective for AMD. Moreover, we demonstrate that this effect is independent of the two prominent factor H risk determinants rs1061170 (CFH:Y402H, causative) and rs2274700 (CFH:A473A, protective). Functional analyses allocate the risk modifying mechanism of the CNP to the local balance between CFHR3, CFHR1 and factor H in complement regulation. CFHR3 and CFHR1 proteins are both complement regulators. CFHR3 acts as cofactor for factor I in inactivating C3b and CFHR1 blocks the terminal complement pathway. Both, CFHR3 and CFHR1, lack decay acceleration activity. The three proteins CFHR3, CFHR1 and factor H bind to similar sites on C3b and thus CFHR3 and CFHR1 compete with factor H for C3b binding. As a consequence, a homeostatic balance between CFHR3, CFHR1 and factor H determines complement activities which subsequently influences progression of AMD.
The homozygous deletion of a chromosomal segment that includes gene loci CFHR3
and CFHR1 results in a complete deficiency of the corresponding proteins in plasma and was suggested a functional candidate for one of the two common protective CFH haplotypes (10,13). Furthermore, the associated AMD risk reduction of the corresponding haplotype was reported to be independent of the causative SNP rs1061170 which was confirmed in subsequent studies (12, 28) . These studies, In the present study we genotyped ΔCFHR3/CFHR1 in a large cohort of 530 AMD patients and 313 control persons. This provides sufficient statistical power, allowing the detection of an AMD protective effect of ΔCFHR3/CFHR1 which remained statistically significant even after conditioning for rs1061170 and/or rs2274700. As a consequence, our findings suggest ΔCFHR3/CFHR1 by itself is an AMD risk factor independent of the known factor H variants.
Earlier studies defined rs2274700 as a major risk variant (3, 25) ; however our results clearly show that the minor allele of rs2274700 exerts a protective effect and occurs on two common protective haplotypes, but not on the common neutral or the common risk haplotypes. This is well in agreement with studies by Hughes et al. (10) and Spencer et al. (12) who analyzed among other factor H variants, SNPs that were in high LD with rs2274700 (r 2 > 0.8) (25, 29) . Interestingly, when comparing the absolute effect sizes, rs2274700 appears to exceed the effect of rs1061170 (2.8 fold vs. 2.2 risk alteration, respectively). Considering the minor allele frequencies of both risk variants revealed similar magnitude in the control sample (rs1061170: 40.6 % vs. rs2274700: 43.4 %) thereby elevating this protective variant to the major risk determinant of this locus. Our association data suggest that the deletion or its tagged P2 haplotype explains part of the protective effect of rs2274700. Consequently, the remaining risk reduction might be due to the second protective haplotype P1 and eventually to its putatively functional SNP rs800292 (CFH:I62V). Nevertheless, we cannot exclude that both protective haplotypes together tagged by rs2274700 share a so far unknown, functional variant.
The ΔCFHR3/CFHR1 deletion as an independent protective factor for AMD pathology suggests that CFHR3 and/or CFHR1 protein function confers risk to AMD.
Therefore, we characterized CFHR3 functions and investigated how the absence of CFHR3 and CFHR1 proteins alter AMD risk. Here, we identify CFHR3 as a novel human complement regulator. CFHR3 acts as a cofactor for the serine protease factor I for degradation and inactivation of C3b. However, CFHR3 mediated cofactor activity is lower as that of factor H. Previous studies reported very low or no cofactor activity of CFHR3 alone, but an enhanced effect on cofactor activity of factor H (30).
However, in these studies radio-labeled C3b was used and possibly the labeling How can such a loss of regulatory functions be protective to AMD? As shown in this study, CFHR3 and also CFHR1 compete with factor H for binding to C3b and thereby modulate local factor H mediated complement activity. A similar replacement effect of factor H binding to C3b has been reported for a C-terminal fragment of factor H (ΔSCR19-20) (33) . We conclude that binding of factor H to C3b is increased in case of CFHR3/CFHR1 deficiency. As factor H is a very potent regulator that exerts at least two regulatory functions, decay acceleration and cofactor activity, increased factor H binding to C3b also enhances complement regulation on the level of C3
convertase. This enhanced regulation by factor H is confirmed in hemolytic assays with CFHR3 and CFHR1 deficient human plasma. Addition of CFHR3 or CFHR1 enhances hemolysis of erythrocytes in contrast to the addition of factor H. However, these proteins represent complement regulators of the C3 and C5 convertase (table   2) and presumably regulate complement activation at specific locations and ensure inactivation of the complement activation cascade. That deficiency of CFHR1 and CFHR3 results in a loss of regulatory functions is concluded as in DEAP HUS this deficiency predisposes to the development of autoantibodies to factor H in early ages (12, 14) . In HUS ΔCFHR3/CFHR1 is frequently associated with the presence of factor H autoantibodies, however, a small fraction of HUS patients show CFHR3/CFHR1 deficiency but lack autoantibodies to factor H. At present it is unclear, why in this group of patients the CFHR3/CFHR1 deficiency increased the risk for atypical HUS.
Presumably CFHR3 and CFHR1 deficiency is associated with an unknown complement enhancing factors in these patients.
Two CFHR1 variant with three amino acid exchanges in SCR 3 (H36.1-YVQ and H36.2-HLE) were initially identified (20) . The H36.1-YVQ variant has now been associated with an enhanced risk for the development of HUS (34). The H36.1-YVQ resembles the sequence of SCR 18 of factor H and is supposed to replace factor H from C3b with higher efficiency than the H36.2-HLE variant. Whether the frequency of the two CFHR1 variants also affects the risk of AMD has not been determined yet.
In summary, this study provides evidence that ΔCFHR3/CFHR1 represents a loss of two complement regulators and affects local factor H binding, which results in increased factor H mediated regulation. This is in agreement with our genetic data, which demonstrate that ΔCFHR3/CFHR1 confers a protective effect against AMD 
Materials and Methods
Subjects and Clinical Assessment
Cases and controls were recruited at the Department of Ophthalmology, University of
Bonn (26) and at the University Eye Clinic Würzburg (Frankonian AMD Study) (35) .
The total study comprised 530 non-familial AMD patients and 313 unrelated control individuals. The mean age at examination was 78.0 yrs for AMD patients (SD, 6.6 yrs; range: 56 -95 yrs) and 77.2 yrs for controls (SD, 6.7 yrs; range: 60 -99 yrs).
The control subjects were free of macular changes such as drusen, pigmentary alterations, or diabetic maculopathy. The study was approved by the Ethics
Committee of the University of Würzburg and the University of Bonn and adhered to the tenets of the Declaration of Helsinki. All subjects were informed as to the nature of the study and signed a written consent prior to blood withdrawal.
Genotyping
Genomic DNA was extracted from peripheral blood leukocytes according to 
Statistical analysis
Deviations from Hardy-Weinberg equilibrium (HWE) were assessed for statistical significance using PLINK v1. Logistic regression analysis and conditional analysis was performed assuming a logadditive genetic model implemented in PLINK v1.07.
Significant differences between two data groups in chemotaxis and binding assays were analyzed by the unpaired t-test. Values of *P≤0.05, **P≤0.01, ***P≤0.001 were considered statistically significant.
Recombinant proteins and Western Blot analysis
Recombinant CFHR3 was expressed with the bacculovirus system as described (30) and CFHR1 in Pichia pastoris (7,34). All proteins were purified by Nickel chelate affinity chromatography (7). Recombinant proteins were separated by SDS PAGE and visualized by silverstaining. Normal human plasma (HP) and CFHR1 and CFHR3 deficient plasma (ΔCFHR3/CFHR1) was obtained from healthy volunteers, Jena, Germany, upon informed consent. Depletion of factor H and CFHR1 and CFHR3 was performed as described earlier (7). Briefly factor H-depleted human plasma was prepared by immunoadsorbance of factor H from normal human plasma (NHS). Polyclonal factor H antiserum (Merck Biosciences) was covalently coupled to a 1-ml HiTrap NHS (N-hydroxy succimide) column (GE Health Care) and incubated with NHS. Factor H depletion was confirmed by Western blotting. Human plasma was separated by SDS PAGE, transferred to a membrane and immunoblotted using polyclonal antiserum to CFHR3 and CFHR1 as previously described (19) Vitronectin was purchased from BD Biosciences, C3b, C3d, factor H and Factor I from Comptech. A monoclonal antibody (4H9) to CFHR3 was generated.
Cofactor assay
Cofactor activity CFHR3, CFHR1 and factor H was analyzed by measuring factor-I mediated degradation of C3b following SDS-Page and Western Blot analysis. 
Chemotaxis assay
To obtain BM-derived neutrophils, femurs, tibias, and humeri of BALB/c mice were flushed with sterile PBS. The migration of BM-derived neutrophils was determined using a 48-well microchemotaxis chamber (Neuro Probe) with polycarbonate filters (pore size, 3 μm). Twofold serial dilutions (1:2 to 1:64) of CFHR3 (80 µg/ml, 1.6 µM), or CFHR1 (80 µg/ml, 1.8 µM), or factor H (80 µg/ml, 0.5 µM)-treated human factor H deficient plasma activated by addition of sheep red blood cells were used and diluted using 2% BSA-GBSS (Sigma-Aldrich). Thirty microliters of the diluted plasma were added to the lower well to act as a chemoattractant for 50 μl of neutrophils (10 numbers of neutrophils per square micrometer migrating to the lower surface of the membrane were determined microscopically (≥20 high power fields, 32× magnification).
ELISA
To investigate CFHR3 regulation of the C3 convertase, the C3 convertase was generated by incubation of C3b (5 μg/ml) and C3 (50 μg/ml) with Factor D (2,5 μg/ml), Properdin (2,5 µg/ml) and Factor B (5 μg/ml) in activation buffer C (20 mM
Hepes, 144 mM NaCl, 7 mM MgCl 2 , 2mM NiCl 2 , 10mM EGTA, pH 7.4). Activity of C3
convertase was determined by C3a generation after incubation of constant amounts of C3 (50 μg/ml) and increasing concentrations of CFHR3 (25 and 50 μg/ml, 0.5 and 1 µM), factor H (50 µg/ml, 0.32 µM) or 25 μg/ml human serum albumine (HSA). The respective allele-specific OR (equal to the heterozygous genotype's OR) of the additive model is shown. The respective homozygote's OR can be directly obtained by the square of the heterozygote's OR. 
